Novo Nordisk A/S
F:NOVC

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOVC
Watchlist
Price: 90.7 EUR -1.52% Market Closed
Market Cap: €203.5B

Net Margin

32.9%
Current
Declining
by 1.5%
vs 3-y average of 34.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.9%
=
Net Income
kr103.8B
/
Revenue
kr315.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.9%
=
Net Income
€103.8B
/
Revenue
kr315.6B

Peer Comparison

Country Company Market Cap Net
Margin
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
DE
Bayer AG
XETRA:BAYN
43.7B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...

Market Distribution

Higher than 85% of companies in Denmark
Percentile
85th
Based on 559 companies
85th percentile
32.9%
Low
-18 280.1% — 1.4%
Typical Range
1.4% — 15.8%
High
15.8% — 2 389.6%
Distribution Statistics
Denmark
Min -18 280.1%
30th Percentile 1.4%
Median 3.9%
70th Percentile 15.8%
Max 2 389.6%

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
32.9%
=
Net Income
kr103.8B
/
Revenue
kr315.6B
What is Novo Nordisk A/S's current Net Margin?

The current Net Margin for Novo Nordisk A/S is 32.9%, which is below its 3-year median of 34.4%.

How has Net Margin changed over time?

Over the last 3 years, Novo Nordisk A/S’s Net Margin has increased from 31.6% to 32.9%. During this period, it reached a low of 31.4% on Dec 31, 2022 and a high of 36.6% on Mar 31, 2024.

Back to Top